Novozymes is exploring the potential of gut health supplements to support users of GLP-1 weight loss drugs. In an interview with CNBC, Novozymes CEO Ester Baiget stated that the company is collaborating with Novo Nordisk on a study to evaluate whether a combination of probiotics, prebiotics, and postbiotics can help GLP-1 weight loss patients feel better and serve an adjunctive role during treatment.